IGFBP6 and lung carcinoma: In a study based on lung cancer cell lines, transgenic and transplantable murine lung cancer models, and a human normal-malignant lung tissue array, the sensitivity to the Smo inhibitor cyclopamine correlated with low IGFBP-6 [78].